Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alphawave reports record bookings, withholds guidance amid trade uncertainty

(Sharecast News) - Alphawave IP Group reported record annual bookings for 2024 on Thursday, reflecting strong demand for its high-speed connectivity IP, despite a drop in total revenue and a wider operating loss, although it withheld guidance for the current financial year amid global trade uncertainty. The London-listed company, which trades as Alphawave Semi, said total bookings rose 34% year-on-year to a record $515.5m, driven by a 45% increase in licence and non-recurring engineering (NRE) bookings.

However, full-year revenue fell 4% to $307.6m, with a sharp 68% decline in royalties and silicon sales more than offsetting the 54% growth in licence and NRE revenue.

Adjusted EBITDA came in at $51.1m, down 18%, in line with guidance.

The firm's statutory operating loss widened to $32.8m from $19.4m in the prior year, and net losses narrowed modestly to $42.5m from $51m.

Cash generation from operations declined 16% to $13.5m, while cash and equivalents increased 78% to $180.2m.

Net debt rose to $171.9m from $119.1m a year earlier, reflecting ongoing investment across the business.

Alphawave maintained 103 revenue-generating end-customers, in line with the prior year, and expanded its IP portfolio to over 240 silicon IPs.

The company launched a dedicated chiplet group in 2024 and achieved industry-first products, including a multi-protocol I/O chiplet, while securing design wins for AI accelerators and high-speed data centre applications.

Notable customer wins included 3nm high-speed IP licensing deals in 800G and 1.6T applications for AI and HPC workloads.

The company also started recognising revenue in its connectivity products unit, and introduced next-generation digital signal processors supporting long-range data transmission.

Alphawave said it also deepened its ecosystem relationships through continued partnerships with TSMC, Samsung and Arm, and joined the UALink and OIF consortiums.

In December, it signed a strategic partnership with Siemens EDA to expand global sales reach.

Looking ahead, the company said it expected to complete business integration in 2025 and begin delivering silicon products for AI and data centres.

However, Alphawave withheld formal guidance for 2025 citing economic uncertainty and the impact of new global tariff regimes.

Despite the near-term uncertainties, its management said it remained confident in the company's long-term growth trajectory.

"In 2024, we signed a record $515.5m in bookings reflecting the strong demand for our technology and the deep trust our customers place in us," said president and chief executive officer Tony Pialis.

"Throughout the year, we strengthened key partnerships, expanded our global reach, and continued to lead in next-generation connectivity and chiplet innovation."

Pialis said the company's position "at the forefront of the industry", working with "some of the world's most respected" data centre and AI partners, underscored its leadership and growing influence.

"With a leading connectivity portfolio, a talented team, and a significant market opportunity ahead, we are confident in the long-term potential of our business."

At 0907 BST, shares in Alphawave IP Group were down 0.27% at 120.47p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.